The strongest evidence yet for covid immunity bat coronaviruses cross-reactivity arrived this week. In two companion papers published in PLOS Biology, researchers at the Pirbright Institute and King’s College London show that antibodies from people who recovered from COVID-19 neutralize a range of closely related bat coronaviruses in the lab, and that the bat viruses most likely to spill over into humans are also the ones our immune systems recognize best.
Here is what they found, and where I draw the line on the claims.
The study behind the headline
Joint work from the Pirbright Institute and King’s College London, funded by BBSRC, Wellcome, and the Medical Research Council, published 1 October 2026 in PLOS Biology. The first paper maps which viruses can infect which species and how visible they are to our immunity; the second pinpoints where broadly neutralizing antibodies bind on the spike.
- Nazia Thakur and colleagues: “Breadth of ACE2 receptor usage predicts host range and antigenic relatedness across bat sarbecoviruses”
- Ayush Upadhyay and colleagues: “Targeting of conserved spike epitopes enables broad antibody neutralisation of diverse bat sarbecoviruses”
What “cross-reactivity” actually means
Your immune system learns shapes, mostly pieces of the spike protein, not virus names. When a related virus shares those shapes, antibodies made against the first can still grab the second. The bat viruses here are sarbecoviruses, the subgroup containing SARS-CoV-1 and SARS-CoV-2. Close relatives share long stretches of spike sequence; distant ones do not.
How covid immunity and bat coronaviruses cross-reactivity was measured in the lab
The first paper tested 15 bat coronavirus spike proteins against ACE2 receptors from 34 species, from humans and livestock to rodents and candidate intermediate hosts. The “generalist” viruses, able to use ACE2 from many species, sat mostly in the same evolutionary group as SARS-CoV-2, including the BANAL viruses from Laos. Viruses from other branches, including a new UK bat coronavirus called RhGB07, used receptors from far fewer hosts.
Then the immunity experiments. Blood from people who had recovered from COVID-19 was tested against the virus panel: the antibodies neutralized the closely related bat coronaviruses, with lower but detectable neutralization against more distant ones. The second paper isolated monoclonal antibodies recognizing a wide range of sarbecoviruses and mapped their binding sites to conserved spike regions.
What this could mean for pandemic preparedness
First, a fortunate alignment. Lead author Dr. Nazia Thakur said the bat coronaviruses most likely to spill over are also those most likely to be recognized by existing COVID-19 immunity, though spillover risk “can never be eliminated.”
Second, the conserved spike regions the second paper mapped are what vaccine designers want: parts of the virus stable across the family. Pirbright’s Dr. Dalan Bailey said the findings suggest pan-sarbecovirus vaccines “may be achievable.”
Third, better threat ranking. Host range, receptor usage, and immune recognition together separate high-risk viruses from background noise more cleanly than any single measure, a practical upgrade for surveillance.
The limits I would flag
Neutralization in a dish is not protection in a person. These assays show antibodies blocking viruses in cell culture, not proof that a previously infected person would be protected against disease from a novel spillover.
Protection weakens with distance. Cross-neutralization was real but lower against the more distantly related sarbecoviruses. Those tend to be specialists with narrow host ranges, arguably less threatening, but the gradient should not be smoothed over.
Antibodies are only part of immunity. This work covers the antibody arm only. T-cell responses, which matter for preventing severe disease, were not studied here.
Viruses keep evolving. The study found omicron-lineage variants picked up receptor-binding-domain mutations that shifted ACE2 usage across species. A virus familiar to our immunity today may look different after further mutation in animal reservoirs.
Questions researchers are being asked
Does having had COVID-19 protect me from the next bat coronavirus?
Not in any guaranteeable sense. Your antibodies would likely recognize a close SARS-CoV-2 relative better than a never-exposed person’s would. A head start, not a shield.
What would a pan-sarbecovirus vaccine be?
A vaccine built around the conserved spike regions this study mapped, aimed at the whole sarbecovirus family rather than one virus at a time. A research goal, not a product yet.
Does this make the next coronavirus pandemic less likely?
Spillover risk can never be eliminated. The study suggests the barrier may be higher than feared for the closest SARS-CoV-2 relatives, also the most plausible spillover candidates. Good news with error bars, not a verdict.
My read
The study answers two questions at once: which viruses are credible threats, and how much does existing immunity cover them. Both answers point the same encouraging way, and the conserved-epitope mapping gives vaccine developers something concrete to build on. Next: animal-model confirmation and field surveillance using this framework.
I have written before about why promising findings need reproducible science behind them before they change practice. This result deserves follow-up, not headlines declaring the problem solved.
Sources
- Medical Xpress, “COVID-19 immunity may help protect against other bat coronaviruses,” Oct 2026.
- Thakur N. et al., PLOS Biology (2026), doi:10.1371/journal.pbio.3003944.
- Upadhyay A. et al., PLOS Biology (2026), doi:10.1371/journal.pbio.3003882.